Should You Buy Joint Corp (JYNT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
9.560
1 Day change
52 Week Range
13.470
Analysis Updated At
2026/01/30
Not a good buy right now. JYNT is sitting on/just below near-term support (~9.52) with bearish momentum (MACD histogram negative and expanding) and very defensive options positioning (put-heavy open interest). With no proprietary buy signals today and analysts broadly cutting targets on soft clinic fundamentals, the risk of support breaking outweighs the upside for an impatient buyer. I would only turn constructive if it reclaims the pivot area (~10.00) and holds above it.
Technical Analysis
Trend/momentum: Bearish-to-neutral. MACD histogram (-0.0521) is below zero and negatively expanding, indicating downside momentum is building. RSI(6) at ~40.6 is weak-neutral (not oversold), so there isn’t a clear mean-reversion buy signal yet. Moving averages are converging, consistent with a transition zone, but momentum currently favors sellers.
Key levels: Price 9.52 is essentially at S1 (9.525); a clean break increases odds of a move toward S2 (9.228). Upside resistance is the pivot at 10.005, then R1 10.484.
Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bearish/defensive skew. Put open interest (2883) far exceeds call open interest (478), driving a very high OI put/call ratio (6.03), which typically signals heavy hedging or bearish positioning.
Activity: No options volume today (0), so the signal is from positioning rather than fresh flow.
Volatility: 30D IV ~55.3% with IV rank ~20 and IV percentile ~58; IV has been higher recently (5D/10D IV averages ~75–81), suggesting volatility has been coming down after being elevated.
Technical Summary
Sell
7
Buy
4
Positive Catalysts
Technically, the stock is at a clearly defined support zone (~9.52), which can produce a short bounce if it holds. Revenue grew +5.74% YoY in 2025/Q3 and gross margin improved (+2.33% YoY), which supports the longer-term franchising/margin-improvement narrative. Pattern-based stats provided indicate a favorable 1-month drift (+9.67% probability-weighted expectation) if support holds and sentiment stabilizes.
Neutral/Negative Catalysts
Options positioning is extremely put-heavy (OI P/C 6.03), a strongly defensive signal. Fundamentals in the latest quarter show sharp earnings deterioration (net income and EPS down >100% YoY), aligning with analyst commentary about softness in new patient acquisition and slower refranchising progress. No positive news catalysts were reported in the last week. No notable hedge fund/insider buying trends were flagged, and no recent Congress trading data is available.
Financial Performance
Latest quarter: 2025/Q3. Revenue rose to 13,380,685 (+5.74% YoY), and gross margin increased to 76.77 (+2.33% YoY), showing some operating improvement. However, profitability deteriorated sharply: net income fell to 855,009 (down -127.01% YoY) and EPS dropped to 0.06 (down -128.57% YoY), indicating earnings pressure despite revenue growth—consistent with the idea that the turnaround/refranchising is taking longer and near-term results are soft.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: net negative. On 2025-11-07, B. Riley downgraded to Neutral from Buy and cut the price target to $9 from $18, citing deteriorating trends and weak comps/new patient acquisition. The same day, Lake Street kept Buy but cut PT to $11 (from $16), and Roth kept Buy but trimmed PT to $14 (from $15).
Wall Street pros vs cons: Pros—some analysts still see longer-term margin/FCF inflection once refranchising completes. Cons—near-term clinic-level fundamentals are soft, refranchising is slower than expected, and targets were cut meaningfully with at least one downgrade, signaling reduced confidence in the timing of recovery.
Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 9.560
Low
9
Averages
11.33
High
14
Current: 9.560
Low
9
Averages
11.33
High
14
B. Riley
B. Riley
Buy -> Neutral
downgrade
$18 -> $9
AI Analysis
2025-11-07
Reason
B. Riley
B. Riley
Price Target
$18 -> $9
AI Analysis
2025-11-07
downgrade
Buy -> Neutral
Reason
B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.
Lake Street
Ryan Meyers
Buy
downgrade
$16 -> $11
2025-11-07
Reason
Lake Street
Ryan Meyers
Price Target
$16 -> $11
2025-11-07
downgrade
Buy
Reason
Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $11 from $16 and keeps a Buy rating on the shares. The transition toward a fully franchised model has taken longer than originally expected, says the analyst, who lowers the firm's price target as the underlying fundamentals at the clinic level remain soft.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JYNT
